Article
TPMT genetic variants are associated with increased rejection with azathioprine use in heart transplantation.
Pharmacogenetics and genomics - 1 Dec 2013
Liang Jackson J, Geske Jennifer R, Boilson Barry A, Frantz Robert P, Edwards Brooks S, Kushwaha Sudhir S, Kremers Walter K, Weinshilboum Richard M, Pereira Naveen L
Abstract excerpt
OBJECTIVES: Azathioprine (AZA) is an important immunosuppressant drug used in heart transplantation (HTX). Consensus guidelines recommend that patients with thiopurine S-methyltransferase (TPMT) genetic variants be started on lower AZA dose because of higher active metabolite levels and risk of adverse events. However, in-vitro lymphocyte proliferation assays performed in participants with inactive TPMT alleles...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
